Top

Betty Kim, MD, PhD, FRCSC, FAANS

Department of Neurosurgery, Division of Surgery

Meet Yon Son Betty Kim, M.D., Ph.D.

In the News

Study opens new avenue for immunotherapy drug development

Scientists develop novel mRNA delivery method using extracellular vesicles

Physician-scientist: I found my sense of belonging at MD Anderson

2021 class of Andrew Sabin Family Fellows: Francesca Cole, Ph.D.; Michael Curran, Ph.D.; Yejing Ge, Ph.D.; Vivek Subbiah, M.D.; Ching-Wei Tzeng, M.D.; Sangeeta Goswami, M.D., Ph.D.; Betty Y.S. Kim, M.D., Ph.D.; Pavlos Msaouel, M.D., Ph.D.; Michelle Hildebrandt, Ph.D.; Ethan Ludmir, M.D.

MD Anderson announces 2021 class of Andrew Sabin Family Fellows

Nanomedicine: Small particles with huge possibilities for cancer care

Present Title & Affiliation

Primary Appointment

Professor, Department of Neurosurgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Neurosurgery, Baylor College of Medicine, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Neurosurgery, Baylor College of Medicine, Houston, TX

Research Interests

As a Physician Scientist, Dr. Kim’s laboratory takes a multidisciplinary approach to the research of solid tumors with a specific focus on malignant primary and metastatic brain tumors. Her work has been published in journals such as the New England Journal of Medicine, Nature, Nature Nanotechnology, Nature Biomedical Engineering, Nature Reviews Immunology and Nature Reviews Drug Discovery. Dr. Kim’s lab is interested in understanding the molecular cross-talk that occurs between tumor and stromal cells within the tumor immune-microenvironment, while also developing multiple patented therapeutic strategies to inhibit tumorigenesis. Her current research primarily focuses on finding new ways to promote immune recognition of glioma cells to boost the efficacies of cancer immunotherapies. Her group also pursues the identification of predictive and prognostic biomarkers for personalized medicine in the context of brain tumors.

Education & Training

Degree-Granting Education

2008	University of Toronto, Toronto, CA, Biomaterials and Biomedical Engineering, PhD
2002	McMaster University, Hamilton, CA, Medicine, MD
1998	Oxford University, Oxfordshire, GB, Post-Colonial Literature, Visiting Scholar
1998	McGill University, Montreal, CA, Anatomy and Cell Biology, BSc (Hon)

Postgraduate Training

2012-2013	Clinical Fellowship, Skull Base Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas
2011-2012	CIP, Clinical Investigator, Royal College of Surgeons
2011-2012	Clinical Fellowship, Neurosurgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
2011-2012	FRCSC, Neurologic Surgeons, Royal College of Surgeons
2006-2012	Clinician Investigator Program, Neurologic Surgery, University of Toronto, Toronto
2005-2011	Clinical Residency, Neurosurgery, University of Toronto, Toronto
2002-2005	Clinical Residency, Neurosurgery, University of Ottawa, Ottawa
2000-2001	Research Fellowship, Neurologic Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
2000-2000	Medical Research Scholar, Neurology and Oncology, Kennedy Krieger Institute, Baltimore, Maryland

Board Certifications

2012	Neurosurgery, Royal College of Physicians and Surgeons, Canada

Experience & Service

Academic Appointments

Associate Professor, Department of Neurosurgery, Baylor College of Medicine, Houston, TX, 2019 - 2022

Associate Professor, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022

Associate Professor, Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, 2017 - 2019

Assistant Professor, Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, 2014 - 2019

Assistant Professor, Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 2014 - 2019

Assistant Professor, Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, 2013 - 2017

Administrative Appointments/Responsibilities

Co-Chair, GBM TeamLab Science, Break Through Cancer, Boston, MA, 2024 - Present

Chair, Ascending Senior Faculty Committee, Department of Chief Academic Office, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present

Leadership Member, GBM Extended Leadership Committee, Break Through Cancer, Boston, MA, 2021 - Present

Principal Investigator, GBM Clinical Trial, MD Anderson, Break Through Cancer, Boston, MA, 2021 - Present

Co-Director, Brain SPORE Animal Core, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024

Director, Mayo Clinic Florida Neurosurgery Research, Jacksonville, 2015 - 2019

Other Appointments/Responsibilities

Member, Scientific Advisory Council, American Brain Tumor Association, 2024 - Present

Co-Chair Basic Science Special Interest Track, Brain Tumor, Society of Neuro-Oncology (SNO), 2023 - Present

Co-Lead (Neurosurgery), Radiosurgery Oversight Team: UT-MD Anderson, Houston, TX, 2023 - Present

Principle Investigator, GBM Clinical Trial Team MD Anderson, Brain Tumor, Break Through Cancer, 2023 - Present

Member, Brain Cancers Forum, White House Cancer Moonshot Program, Washington, DC, 2023 - Present

Advisory Member, Image Guided Cancer Therapy (IGCT) Research Program: UT-MD Anderson, Houston, TX, 2022 - Present

Advisory Board Member, BrainUp, Chicago, IL, 2022 - Present

Member, Core Facility Oversight Board, UT MD Anderson, Houston, TN, 2022 - Present

Extended Leadership Team (GBM), Break Through Cancer, Boston, MA, 2021 - Present

Co-Director, Mayo Clinic Skull Base and Endoscopy Course, Jacksonville, 2015 - 2019

Co-Director, Mayo Clinic Florida CNS Tumor Biobank, Jacksonville, 2015 - 2019

Course Director, Mayo Clinic Clearpoint Neuroblation Course, Jacksonville, 2015 - 2018

Institutional Committee Activities

Member, Emerging Leader Workshop Committee, 2024 - Present

Chair, Ascending Senior Faculty Committee, 2024 - Present

Member, Search Committee, Chairman of Plastic Surgery, 2023 - Present

Member, Core Facilities Oversight Board, 2022 - Present

Member, Brain Tumor Program Data Governance Committee, 2021 - 2023

Co-Lead, Radiosurgery Review Committee, 2020 - Present

Member, Brain Tumor Program Tissue Utilization Committee, 2020 - Present

Member, TMC3 Science Think Tank, 2020 - 2023

Member, Brain Metastasis Clinic, 2020 - Present

Honors & Awards

2024	Elected Fellow, American Society for Clinical Investigation
2023	Regina Rogers Family Award, UT-MD Anderson Cancer Center
2023	Elected Fellow, American Institute for Medical and Biological Engineering (AIMBE)
2022	Texas Business Women's Award, UT-MD Anderson Cancer Center
2021	Sabin Family Foundation Fellowship Award, Sabin Family Foundation
2016	Forty Stars of Forty Under Florida - Florida Trend Magazine
2012	Detweiler Travelling Fellowship - Royal College of Physicians and Surgeons
2010	Sopman Humanitarian Award - University of Toronto
2009	National Research Award - Canadian Federation of University Women, First place
2009	Mark Bernstein Award in Neurosurgery - University of Toronto, Toronto, Canada
2009	National Research Award for Specialty Residents - Royal College of Physicians
2009	Top Gun American Association of Neurological Surgeons, 1st place
2008	Javenthey Soobiah Scholarship - University of Toronto School of Medicine
2008	CIHR/Brain Star Award - Canadian Institutes of Health Research, Best research
2008	AANS/NREF Fellowship - American Association of Neurological Surgeons
2008	Restracomp Research Training Grant - Hospital for Sick Children, 1st place
2008	Thomas Morley Best Original Research - University of Toronto
2008	Time Posters Fellowship - University of Toronto School of Medicine
2008	McKenzie Award - Canadian Neurological Sciences, Best neuroscience research
2008	Joseph M. West Family Memorial Scholarship - University of Toronto
2008	Gallie-Bateman Research Award - Department of Surgery, University of Toronto
2005	Joseph M. West Family Memorial Fund - University of Toronto
2005	Heart and Stroke and Foundation of Canada - Medical Research Scholar Award
2005	Price Water House Research Excellence Award - University of Toronto
2005	Thomas L. Friedlich Award in Surgical Sciences Research - University of Toronto
2005	Natural Sciences & Engineering Research Canada (NSERC) Grant
2005	Charles F. Fell Scholarship - University of Toronto School of Medicine
2005	Post-Graduate Medicine Research Award - University of Toronto
2005	Chisholm Memorial Research Fellowship

Professional Memberships

BrainUP

2022 - Present

Neurosurgical Society of America

2019 - Present

Mayo Clinic Center for Regenerative Medicine

2016 - 2019

American Association for the Advancement of Science

2016 - Present

American Association of Neurological Surgeons

2015 - Present

Florida Center for Brain Tumor Research

2015 - 2019

American Brain Tumor Association Scientific Advisory

2014 - Present

Mayo Clinic Florida Neuroscience Focused Research Committee

2014 - 2019

American Medical Association

2013 - Present

American Association of Cancer Research

2013 - Present

Royal College of Physicians and Surgeons of Canada

2013 - Present

Society of Neuroscience

2013 - Present

Royal College of Physicians and Surgeons of Canada

2012 - Present

World Federation of Neurological Surgeons

2007 - Present

American College of Surgeons

2007 - Present

Women in Neurosurgery

2006 - Present

Congress of Neurological Surgeons

2005 - Present

Society for Neuro-Oncology

2005 - Present

Selected Publications

Peer-Reviewed Articles

Schrank BR, Wang Y, Wu A, Tran N, Lee D, Edwards J, Huntoon K, Dong S, Ha J, Ma Y, Grippin AJ, Jeong SD, Antony A, Chang M, Kang M, Gallup TD, Koong AC, Li J, Yun K, Kim BYS, Jiang W. An antibody-toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nat Cancer, 2025. e-Pub 2025. PMID: 40000910.
Wang Y, Schrank BR, Jiang W, Kim BYS. Learning what keeps nanomedicines in tumours. Nat Biomed Eng, 2024. e-Pub 2024. PMID: 39271934.
Huntoon, K, Lee, DY, Dong, S, Antony, A, Kim, YB, Jiang, W. Targeting phagocytosis to enhance antitumor immunity. Trends in Cancer 10(6):571, 2024. e-Pub 2024. PMID: 37839974.
Sun L, Niu H, Wu Y, Don S, Li X, Kim BYS, Liu C, Ma Y, Jiang W, Yuan Y. Bio-integrated scaffold facilitates large bone regeneration dominated by endochondral ossification. Bioactive Materials 35(1):208-227, 2024. e-Pub 2024. PMID: 38327823.
Ha JH, Grippin A, Kim BYS, Jiang W. Striking the Balance with PD-1x4-1BB Bispecific Antibody. Cancer Research 84(10):1546-1547, 2024. e-Pub 2024. PMID: 38745496.
Bian X, Yang L, Jiang D, Grippin AJ, Ma Y, Wu S, Dong S, Kim BYS, Jiang W, Yang Z, Li C. Regulation of cerebral blood flow boosts precise brain targeting of vinpocetin-derived ionizable-lipidoid nanoparticles. Nature Communications 15(1):3987, 2024. e-Pub 2024. PMID: 38734698.
Ene CI, Abi Faraj C, Beckham TH, Andersson CR, Kim BYS, McCutcheon IE, Prabhu SS, McGovern SL, Tom MC, Perni S, Swanson TA, Yeboa DN, Briere TM, Huse JT, Sawaya RE. Response to treatment-naive brain metastases to stereotactic Radiosurgery. Nature Communications 15:3728, 2024. e-Pub 2024.
Lee DY, Huntoon K, Wang Y, Lu Y, Qie Y, Li X, Dong S, Yang Z, Wang L, Li J, Koong A, Jiang W, Kim BYS. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering, 2024. e-Pub 2024. PMID: 38641710.
LI X, Huntoon K, Wang Y, Lee DY, Dong S, Antony A, Walkey C, Kim BYS, Jiang W. Radiation synergizes with IL2/IL15 stimulation to enhance innate immune activation and antitumor immunity 23(3):330-342, 2024. e-Pub 2024. PMID: 37956421.
Wang Y, Deng W, Lee DY, Yan L, Yang M, Gong P, Huntoon K, Lu Y, Lorenzi P, Yang Z, Kim BYS, Jiang W. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Nature Nanotechnology 19(2):255-263, 2024. e-Pub 2024. PMID: 37723279.
Chiang, C, Ma, Y, Hou, YC, Pan, JJ, Chen, SY, Chien, MH, Zhang, ZX, Hsu, WH, Wang, X, Zhang, J, Li, H, Sun, L, Fallen, S, Lee, I, Chen, XY, Chu, YS, Zhang, C, Cheng, TS, Jiang, W, Kim BYS, Reátegui, E, Lee, RJ, Yuan, Y, Liu, HC, Wang, K, Hsiao, M, Huang, CY, Shan, YS, Lee, AS, Lee, LJ. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Nature Communications 14(1), 2023. e-Pub 2023. PMID: 37872156.
Liu, CC, Wang, N, Chen, Y, Inoue, Y, Shue, F, Ren, Y, Wang, M, Qiao, W, Ikezu, TC, Li, Z, Zhao, J, Martens, YA, Doss, SV, Rosenberg, CL, Jeevaratnam, S, Jia, L, Raulin, AC, Qi, F, Zhu, Y, Alnobani, A, Knight, JA, Chen, Y, Linares, C, Kurti, A, Fryer, JD, Zhang, B, Wu, LJ, Kim BYS, Bu, G. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer’s disease. Nature Immunology 24(11):1854-1866, 2023. e-Pub 2023. PMID: 37857825.
Zhang, J, Rima, XY, Wang, X, Nguyen, LT, Huntoon, K, Ma, Y, Palacio, PL, Nguyen, KT, Albert, K, Duong-Thi, MD, Walters, N, Kwak, KJ, Yoon, MJ, Li, H, Doon-Ralls, J, Hisey, CL, Lee, DY, Wang, Y, Ha, JH, Scherler, K, Fallen, S, Lee, I, Palmer, AF, Jiang, W, Magaña, SM, Wang, K, Kim BYS, Lee, LJ, Reátegui, E. Engineering a tunable micropattern-array assay to sort single extracellular vesicles and particles to detect RNA and protein in situ. Journal of Extracellular Vesicles 12(11), 2023. e-Pub 2023. PMID: 37908159.
Dong S, Liu X, Bi Y, Wang Y, Antony A, Lee D, Huntoon K, Jeong S, Ma Y, Li X, Deng W, Schrank BR, Grippin AJ, Ha J, Kang M, Chang M, Zhao Y, Sun R, Sun X, Yang J, Chen J, Tang SK, Lee LJ, Lee AS, Teng L, Wang S, Teng L, Kim BYS, Yang Z, Jiang W. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nature Communications 14(1):6610, 2023. e-Pub 2023. PMID: 37857647.
Altan M, Wang Y, Song J, Welsh J, Tang C, McGovern SL, Wang C, Kim BYS, Weinberg J, Cascade T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. Journal for Immunotherapy of Cancer (JITC), 2023. e-Pub 2023. PMID: 37402581.
Hasanov M, Milton DR, Davies AB, Sirmans E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala CA, Burton EM, Colen RR, Huse JT, Glitza Oliva IC, Chung C, McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg JS, Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SD. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro Oncol 25(7):1310-1320, 2023. e-Pub 2023. PMID: 36510640.
You Y, Tian Y, Yang Z, Shrank B, Huntoon K, Lee D, Gallup T, Ha J, Wang Y, Lee L, Jiang W, Kim BYS, Lan F, Lee A. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 7(7):887-900, 2023. e-Pub 2023. PMID: 36635419.
Huntoon K, Anderson K, Ballman K, Twohyu E, Jiang W, Li J, von Roemeling C, Qie Y, Laack N, Brown P, Roberge D, Kim BYS. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. Neuro-Oncology 25(6):1123-1131, 2023. e-Pub 2023. PMID: 36472389.
Oue H, Yamazaki Y, Qiao W, Yuanxin C, Ren Y, Kurti A, Shue F, Parsons TM, Perkerson RB, Kawatani K, Wang N, Starling SC, Roy B, Mosneag IE, Aikawa T, Holm ML, Liu CC, Inoue Y, Sullivan PM, Asmann YW, Kim BYS, Bu G, Kanekiyo T. LRP1 in vascular mural cells modulates cerebrovascular integrity and function in the presence of APOE4. JCI Insight 8(7), 2023. e-Pub 2023. PMID: 37036005.
Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank BR, Dong S, Gallup TD, Kang M, Zhao H, An Y, Yang Z, Li J, Kim BYS, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nature Nanotechnology 17(12):1332-1341, 2022. e-Pub 2022. PMID: 36357792.
Liu CC, Wang N, Chen Y, Inoue Y, Shue F, Linares C, Kurti A, Fryer JD, Zhang B, Kim BYS, Bu G. Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function. Nature Neuroscience 25(8):1020-1033, 2022. e-Pub 2022. PMID: 35915180.
Li X, Khorsandi S, Wang Y, Santelli J, Huntoon K, Nguyen N, Yang M, Lee D, Lu Y, Kim BYS, Lux C, Mattrey RF, Jiang W, Lux J. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nature Nanotechnology 17(8):891-899, 2022. e-Pub 2022. PMID: 35637356.
Mehta GU, Passer JZ, Raza SM, Kim BYS, Su SY, Kupferman ME, Hanna EY, DeMonte F. The neurosurgical management of sinonasal malignancies involving the anterior skull base. Journal of Neurosurgery 136(6):1583-1591, 2022. e-Pub 2022. PMID: 34624857.
Hsieh RCE, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Lea ST, Taniguchi C, Kim BYS, Chen J, Rudqvisst NP, Curran M. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Science Immunology 7(72), 2022. e-Pub 2022. PMID: 35687697.
George J, Chen Y, Abdelfattah N, Yamamoto K, Gallup TD, Adamson SI, Rybinski B, Srivastava A, Kumar P, Lee MG, Baskin DS, Jiang W, Choi JM, Flavahan W, Chuang JH, Kim BYS, Xu J, Jung SY, Yun K. Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitors. Cancer Research Communication 2(6):402-416, 2022. e-Pub 2022. PMID: 36688010.
Zamler DB, Shingu T, Kahn LM, Huntoon K, Kassab C, Ott M, Tomczak K, Liu J, Li Y, Lai I, Zorilla-Veloz R, Yee C, Rai K, Kim BYS, Watowich SS, Heimberger AB, Draetta GF, Hu J. Immune Landscape of a Genetically Engineered Murine Model of Glioma Compared with Human Glioma. JCI Insight 22(7):1-16, 2022. e-Pub 2022. PMID: 35653194.
Dong, S, Bi, Y, Sun, X, Zhao, Y, Sun, R, Hao, F, Sun, Y, Wang, Y, Li, X, Deng, W, Liu, X, Ha, JH, Teng, L, Gong, P, Xie, J, Kim BYS, Yang, Z, Jiang, W, Teng, L. Dual-Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple-Negative Breast Cancer. Small 18(16), 2022. e-Pub 2022. PMID: 35277914.
Wu, Z, Yang, Z, Sha, D, Ma, Y, Kim, BYS, Jiang, W, Yuan, Y, Liu, C. Injectable, viscoelastic hydrogel precisely regulates developmental tissue regeneration. Chemical Engineering Journal 434, 2022. e-Pub 2022.
Abdelfattah N, Kumar P, J-S L, Flynn W, Gao R, Baskin D, Pichumani K, Ijare O, Wood S, Powell S, Haviland D, Kim BYS, Jiang W, George J, Yun K. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nature Communications 13(1):967, 2022. e-Pub 2022. PMID: 35140215.
Bishop, AJ, Zheng, J, Subramaniam, A, Ghia, AJ, Wang, C, McGovern, SL, Patel, S, Guadagnolo, BA, Mitra, D, Farooqi, AS, Reardon, MJ, Kim, BYS, Guha-Thakurta, N, Li, J, Ravi, V. Cardiac Angiosarcomas: Risk of Brain Metastasis and Hemorrhage Warrants Frequent Surveillance Imaging and Early Intervention. American Journal of Clinical Oncology: Cancer Clinical Trials 45(6):258-263, 2022. e-Pub 2022. PMID: 35588225.
Yang, Z, Shi, J, Xie, J, Wang, Y, Sun, J, Liu, T, Zhao, Y, Zhao, X, Wang, X, Ma, Y, Malkoc, V, Chiang, C, Deng, W, Chen, Y, Fu, Y, Kwak, KJ, Fan, Y, Kang, C, Yin, C, Rhee, J, Bertani, P, Otero, J, Lu, W, Yun, K, Lee, AS, Jiang, W, Teng, L, Kim, BY, Lee, LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nature Biomedical Engineering 5(8):944-945, 2021. e-Pub 2021. PMID: 34131325.
Lee D, Huntoon K, Wang Y, Jiang W, Kim BYS. Harnessing innate immunity using biomaterials for cancer immunotherapy. Advanced Materials 33(27), 2021. e-Pub 2021. PMID: 34050699.
Liu Y, Yang Z, Wang L, Sun L, Kim BYS, Jiang W, Yuan Y, Liu C. Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossification-Mediated Bone Healing. Advanced Science 8(11), 2021. e-Pub 2021. PMID: 34105266.
Sun X, Yu K, Zhou Y, Dong S, Hu W, Sun Y, Li Y, Xie J, Lee RJ, Sun F, Ma Y, Wang S, Kim BYS, Wang Y, Yang Z, Jiang W, Li Y, Teng L. Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. ACS Applied Materials and Interfaces 13(15):18152-18164, 2021. e-Pub 2021. PMID: 33764751.
Yamazaki Y, C-C L, Yamazaki A, Shue F, Martens YA, Chen Y, Qiao W, Kurti A, Que H, Ren Y, Li Y, Aikawa T, Cherukuri Y, Fryer JD, Asmann YW, Kim BYS, Kanekiyo T, Bu G. Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function. Neuron 109(3):438-447.e6, 2021. e-Pub 2021. PMID: 33321072.
Jiang W, Wang Y, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnology 16(1):6-15, 2021. e-Pub 2021. PMID: 33349682.
Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, Yang M, An Y, Tang C, Sanford N, Kim BYS, Jiang W. Assessment of Trends in Second Primary Cancers in Patients with Metastatic Melanoma from 2005 to 2016. JAMA Network Open 3(12), 2020. e-Pub 2020. PMID: 33295975.
Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, Chen J, Kim BYS, Jiang W, Liu Q, Liu J. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade. Clinical Cancer Research 26(7):1712-1724, 2020. e-Pub 2020. PMID: 31848190.
von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, Chan CK, Lee AS, Rosenfeld SS, Yun K, Johnson AJ, Mitchell DA, Jiang W, Kim BYS. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nature Communications 11(1), 2020. e-Pub 2020. PMID: 32198351.
Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Malkoc V, Chiang C, Deng W, Chen Y, Fu Y, Kwak KJ, Fan Y, Kang C, Yin C, Rhee J, Bertani P, Otero J, Lu W, Yun K, Lee AS, Jiang W, Teng L, Kim BYS, Lee LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nature Biomedical Engineering 4(1):69-83, 2020. e-Pub 2020. PMID: 31844155.
Meng F, Sun Y, Lee RJ, Wang G, Zheng X, Zhang H, Fu Y, Yan G, Wang Y, Deng W, Parks E, Kim BYS, Yang Z, Jiang W, Teng L. Folate receptor-targeted albumin nanoparticles based on microfluidic technology to deliver cabazitaxel. Cancers 11(10), 2019. e-Pub 2019. PMID: 31623082.
Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufès C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology 14(7):629-635, 2019. e-Pub 2019. PMID: 31270452.
Chen Y, Liu X, Yuan H, Yang Z, von Roemeling CA, Qie Y, Zhao H, Wang Y, Jiang W, Kim BYS. Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Advanced Science 6(5), 2019. e-Pub 2019. PMID: 30886813.
Chen Y, Hata T, Rehman F, Kang L, Yang L, Kim, BYS, Nguyen JH. Visualization of Hepatocellular Regeneration in Mice After Partial Hepatectomy. Journal of Surgical Research 235:494-500, 2019. e-Pub 2019. PMID: 30691834.
YangZ, Wang L, YuH, Wang R, Gou Y, Zhang M, Kang C, Liu T, lan Y, Wang X, Liu J, Cooper MA, Li X, Yue K, YuY, Wang L, Kim BYS, Jiang W, Sun W. Membrane TLR9 positive neutrophil mediated MPLA protects against fatal bacterial sepsis. Theranostics 9(21):6269-6283, 2019. e-Pub 2019. PMID: 31534550.
Liu Z, Jiang W, Nam J, Moon JJ, Kim BYS. Immunomodulating Nanomedicine for Cancer Therapy. Nano Letters 18(11):6655-6659, 2018. e-Pub 2018. PMID: 30185039.
Yuan HF, Jiang W, Chen Y, Kim BYS. Study of osteocyte behavior by high-resolution intravital imaging following photo-induced ischemia. Molecules 23(11):2874, 2018. e-Pub 2018. PMID: 30400346.
Ioannidis JPA, Kim BYS, Trounson A. How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nature Biomedical Engineering 2(11):797-809, 2018. e-Pub 2018. PMID: 30931172.
Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BYS, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. Journal of Clinical Investigation 128(5):2104-2115, 2018. e-Pub 2018. PMID: 29664018.
Yoon JW, Jiang W, Rutka JT, Huang Y, Kim BYS. Perspectives of Nanotechnology in the Management of Gliomas. Progress in Neurological Surgery 32:196-210, 2018. e-Pub 2018. PMID: 29990985.
von Roemeling CA, Caufield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazelhurst L, Pinkerton AB, Radinsky DC, Tun HW, Kim BYS, Lane AL, Copland JA. Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget 9(1):3-20, 2017. e-Pub 2017. PMID: 29416592.
Chow KH, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, Chen Y, Jiang W, Steindler DA, Neilson EG, Kim BYS, Yun K. S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Research 77(19):5360-5373, 2017. e-Pub 2017. PMID: 28807938.
An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Oncology 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology 12(8):763-769, 2017. e-Pub 2017. PMID: 28459470.
Jiang, W, Von Roemeling, CA, Chen, Y, Qie, Y, Liu, X, Chen, J, Kim, BYS. Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering 1(2):0029, 2017. e-Pub 2017.
Jiang W, Mohamed ASR, Fuller CD, Kim BYS, Tang C, Gunn GB, Hanna EY, Frank SJ, Su SY, Diaz E, Kupferman ME, Beadle BM, Morrison WH, Skinner H, Lai SY, El-Naggar AK, DeMonte F, Rosenthal DI, Garden AS, Phan J. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology 6(4):241-247, 2016. e-Pub 2016. PMID: 26979544.
Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BYS, Radisky DC, Storz P, Copland JA, Tun HW. Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. Oncotarget 7(22):32156-32171, 2016. e-Pub 2016. PMID: 27050077.
Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BYS. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Scientific Reports 6:26269, 2016. e-Pub 2016. PMID: 27197045.
Liu J, Mao K, Jiang S, Jiang W, Chen K, Kim BYS, Liu Q, Jacobs LK. The role of postmastectomy radiotherapy in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy. Oncotarget 7(17):24848-24859, 2016. e-Pub 2016. PMID: 26709538.
Jiang W, Chamberlain PD, Garden AS, Kim BYS, Ma D, Lo EJ, Bell D, Gunn GB, Fuller CD, Rosenthal DI, Beadle BM, Frank SJ, Morrison WH, El-Naggar AK, Glisson BS, Sturgis EM, Phan J. Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. Head and Neck 38:E1459-E1466, 2016. e-Pub 2016. PMID: 26560893.
Jiang W, Huang Y, An Y, Kim BYS. Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano 9(9):8689-8696, 2015. e-Pub 2015. PMID: 26212564.
Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, Liu Q, Jacobs LK. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status. Breast Cancer Research and Treatment 150(2):439-445, 2015. e-Pub 2015. PMID: 25764167.
Kim BYS, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. Journal of Neuro-Oncology 118(2):405-412, 2014. e-Pub 2014. PMID: 24777756.
Kim BYS, Jonasch E, McCutcheon IE. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease. Targeted Oncology 7(2):145-149, 2012. e-Pub 2012. PMID: 22374327.
Kim BYS, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WC. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Letters 8(11):3887-3892, 2008. e-Pub 2008. PMID: 18816147.
Jiang W, Kim BYS, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nature Nanotechnology 3(3):145-150, 2008. e-Pub 2008. PMID: 18654486.
Jiang, W, Singhal, A, Kim, BYS, Zheng, J, Rutka, JT, Wang, C, Chan, WC. Assessing Near-Infrared Quantum Dots for Deep Tissue, Organ, and Animal Imaging Applications. JALA - Journal of the Association for Laboratory Automation 13(1):6-12, 2008. e-Pub 2008.
Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417(6884):74-78, 2002. e-Pub 2002. PMID: 11986668.
Abounader R, Ranganathan S, Kim BYS, Nichols C, Laterra J. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. Journal of Neurochemistry 76(5):1497-1508, 2001. e-Pub 2001. PMID: 11238734.

Invited Articles

Huntoon K, Lee DY, Dong S, Antony A, Kim BYS, Jiang W. Targeting phagocytosis to enhance antitumor immunity. Trends Cancer (Cell Press), 2023. e-Pub 2023. PMID: 37150626.

Abstracts

Chow KH, Park HJ, George J, Chen Y, Gallup A, Jiang W, Kim BYS, Yun K. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. Cancer Research 77(19):5360-5373, 2017. e-Pub 2017. PMID: 28807938.
Chen Y, Jiang W, Qie Y, Liu X, von Roemeling C, Shih K, Wharen RE, Kim BYS. Priming of the brain tumor microenvironment enables improved nanomedicine delivery. Neurosurgery, 2016. e-Pub 2016.
Jiang W, Chen Y, Lin SH, Kim BYS. In vivo imaging and quantification of oxygen tension within solid tumor. Journal of Clinical Oncology, 2016. e-Pub 2016.
Jiang W, Chamberlain PD, Garden AS, Kim BYS, Ma D, Bell D. Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas. Head & Neck, 2016. e-Pub 2016.
Huang Y, Jiang W, Kim BYS. Tumor microenvironment modulation enhances macrophage polarization and T-cell activation resulting in synergized anti-cancer effect. Cancer Research, 2014. e-Pub 2014.
Jiang W, Rodriguez Y, Boehling NS, Prabhu SS, Kim BYS, Hwu P. Circulating myeloid precursor profile as potential marker to differentiate radiation changes from tumor recurrence after brain stereotactic radiosurgery. Cancer Research, 2014. e-Pub 2014.
Kim BYS, Jiang W, Beiko J, Prabhu P, Demonte F, Lang F, Gilbert M. IDH1 status as a diagnostic and prognostic marker for malignant astrocytomas with limited histological specimen: The role of surgical resection. Neuro-Oncology, 2013. e-Pub 2013.

Book Chapters

Lee, DY, Huntoon, K, Kim, BYS, Jiang, W. Challenges and opportunities of nanotechnology in cancer immunotherapy, 197-239, 2022.
Ha JH, Huntoon K, Lee D, Kim BYS, Jiang W. Cancer nanomedicines for enhanced immunotherapy. In: Materials Science and Materials Engineering, 2022.
Yang, Z, Ma, Y, Zhao, H, Yuan, Y, Kim, BYS. Nanotechnology platforms for cancer immunotherapy. In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020.
Gassie K, Bradley B, Wharen RE, Kim BYS, Rabinstein AA, Freeman WD. Management of the Neurosurgical Craniotomy Patient. In: Neuro Critical Care. Oxford University Press 3 rd ed, 2019.
Yoon JW, Jiang W, Rutka JT, Huang Y, Kim BYS. Perspectives of Nanotechnology in the Management of Gliomas. In: Progress of Neurological Surgery. Karger, Berlin, 196-210, 2018.

Books (edited and written)

Kim BYS, Citow JS, Macdonald RL, Refai D. Comprehensive Neurosurgery Board Review. Thieme, 2010.

Letters to the Editor

Jiang W, Liu J, Gullane PJ, Gentili F, Wharen RE, Kim BYS, DeMonte F. Non-contiguous meningeal metastases of olfactory neuroblastoma. Journal of Neuro-Oncology 126: 201-203, 2016.

Less

Selected Presentations & Talks

Local Presentations

2024. Immune-Engineering Approaches for Cancer Therapy. Invited. Houston, Texas, US.
2023. Targeting phagocytosis against cancer and other human diseases. Conference. Targeting phagocytosis against cancer and other human diseases. Houston, TX, US.
2021. Translating Discoveries in Neurosurgical Oncology. Conference. Translating Discoveries in Neurosurgical Oncology, US.
2021. Targeting Phagocytosis as a New Cancer Immunotherapy. Conference. Targeting Phagocytosis as a New Cancer Immunotherapy. Virtual, US.
A Novel mRNA Delivery Platform. Invited. Houston, Texas, US.

Regional Presentations

2023. Development of an Independent Research Program. Conference. Development of an Independent Research Program, TX, US.
2022. Targeting phagocytosis for cancer immunotherapy. Conference. Targeting phagocytosis for cancer immunotherapy, TX, US.
2015. Vasculature remodeling enhances intermediate-sized nanoparticle delivery into solid tumors. Conference. Vasculature remodeling enhances intermediate-sized nanoparticle delivery into solid tumors. Orlando, FL, US.
2014. Nanomedicine for brain tumors. Conference. Nanomedicine for brain tumors. Jacksonville, FL, US.

National Presentations

2024. Immuno-Engineering for Cancer Therapeutics. Visiting. Grand Rounds Lecture Winship Cancer Institute. Decatur, GA, US.
2023. Designing nanomaterials for immune modulation. Conference. Gordon Research Conference: Cancer Nanotechnology, NH, US.
2023. Clinical Trials for Brain Tumors. Conference. Clinical Trials for Brain Tumors. Chicago, IL, US.
2023. NL201 a de novo CD25-independent IL2RbG agonist, synergies with radiation to generate potent anti tumor immunity. Conference. NL201 a de novo CD25-independent IL2RbG agonist, synergies with radiation to generate potent anti tumor immunity. Orlando, FL, US.
2023. Tumor microenvironment modulation by immunotherapy sensitizes solid tumors to radiation. Conference. Tumor microenvironment modulation by immunotherapy sensitizes solid tumors to radiation. Orlando, FL, US.
2023. Development of cationic helical polypeptide-based adjuvants for cancer immunotherapy. Conference. *Sygnature Discovery Scholar-in-Award. Orlando, FL, US.
2023. Breakout Stars in Science - STAT Wunderkind. Conference. STAT News. Boston, MA, US.
2022. Cancer Immunology - Moderator. Conference. Cancer Immunology - Moderator. Dallas, TX, US.
2022. Applying Immuno-Engineering Concepts for Cancer Immunotherapy. Conference. Applying Immuno-Engineering Concepts for Cancer Immunotherapy. Dallas, TX, US.
2022. BioInnovations in Brain Cancer. Conference. BioInnovations in Brain Cancer. Ann Arbor, MI, US.
2022. Social Media and Career Development. Conference. MD Anderson Research Town Hall. Houston, TX, US.
2021. Unleashing the Immune System to Develop Therapeutic Strategies. Conference. Unleashing the Immune System to Develop Therapeutic Strategies, TX, US.
2021. ABTA Discovery Grant Presentation. Conference. ABTA Discovery Grant Presentation. Virtual, US.
2021. Break Through Cancer GBM Team. Conference. MD Anderson Research Town Hall. Houston, TX, US.
2021. Nanomaterials for immunomodulation- a virtual Panel Discussion hosted by Nature Nanotechnology. Conference. Nanomaterials for immunomodulation- a virtual Panel Discussion hosted by Nature Nanotechnology. Virtual, US.
2021. Breakthrough Delivery Science. Conference. Breakthrough Delivery Science. Keynote Speaker, US.
2020. Therapeutic modulation of phagocytosis in glioblastoma activates both innate and adaptive antitumor immunity. Conference. Therapeutic modulation of phagocytosis in glioblastoma activates both innate and adaptive antitumor immunity. Kiawah Island, SC, US.
2020. Targeting brain tumors using therapeutic exosomes. Conference. Targeting brain tumors using therapeutic exosomes. Houston, TX, US.
2019. Novel approaches to glioblastoma therapy using the innate immune system. Conference. Novel approaches to glioblastoma therapy using the innate immune system. Orlando, FL, US.
2018. Re-engineering the immune tumor microenvironment with nanomaterials. Visiting. Re-engineering the immune tumor microenvironment with nanomaterials. Oklahoma City, OK, US.
2017. Re-engineered brain imaging Convergence Technology Summit. Conference. Re-engineered brain imaging Convergence Technology Summit. Atlanta, GA, US.
2017. Selective macrophage-evading nanomedicine as a new targeted drug delivery strategy. Conference. Selective macrophage-evading nanomedicine as a new targeted drug delivery strategy. Mount Snow, RI, US.
2017. Normalizing the tumor microenvironment for enhanced nanomedicine delivery. Conference. Angiogenesis and Tumor Microenvironment Symposium. Amelia Island, FL, US.
2017. CD47 blockade with temozolomide can enhance the therapy in glioblastoma. Conference. CD47 blockade with temozolomide can enhance the therapy in glioblastoma. Washington, DC, US.
2017. Blockade of stearoyl CoA desaturase 1 promotes immunogenic clearance of tumors. Conference. Blockade of stearoyl CoA desaturase 1 promotes immunogenic clearance of tumors. Washington, DC, US.
2017. Priming of the tumor microenvironment enables improved nanomedicine delivery. Conference. Priming of the tumor microenvironment enables improved nanomedicine delivery. Mount Snow, RI, US.
2017. Priming of the brain tumor microenvironment to enable nanomedicine delivery. Conference. Priming of the brain tumor microenvironment to enable nanomedicine delivery. San Diego, CA, US.

International Presentations

2025. Novel Immuno-Engineering Approaches for Cancer. Conference. Bhubaneswar, IN.
2024. mRNA Delivery to Replete Tumor Suppressor Genes in Brain Tumors. Conference. Lisbon, PT.
2024. Bioengineering Gene Delivery for Cancer Therapeutics. Visiting. Oxfordshire, GB.
2023. Targeting phagocytosis against cancer and other human diseases. Conference. Centro di Riferimento Oncologico (CRO). Aviano, IT.
2021. Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era. Conference. Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era. Virtual, US.
2016. Modulating the tumor microenvironment to improve immunotherapy. Conference. Modulating the tumor microenvironment to improve immunotherapy. Dublin, IE.

Formal Peers

2022. Pursuing a career as a surgeon scientist. Invited. Pursuing a career as a surgeon scientist, US.
2022. Targeting phagocytosis as a novel strategy for cancer immunotherapy. Invited. Targeting phagocytosis as a novel strategy for cancer immunotherapy, MI, US.
2021. Neurosurgical Technologies for Bioengineers. Visiting. Neurosurgical Technologies for Bioengineers. Chicago, IL, US.
2021. Cancer Nanotechnology. Invited. Cancer Nanotechnology. Champaign, IL, US.
2021. Modulation of the innate immunity as a therapy for Brain Tumors. Visiting. Modulation of the innate immunity as a therapy for Brain Tumors, US.
2021. Topics in Molecular Medicine. Visiting. Topics in Molecular Medicine. Houston, TX, US.
2021. Translating Discoveries in Neurosurgical Oncology. Invited. Translating Discoveries in Neurosurgical Oncology. Dallas, TX, US.
2020. Bioengineering Seminar Series. Invited. Bioengineering Seminar Series. Cambridge, MA, US.
2019. Bridging innate and adaptive anti-tumor immunity via therapeutic induction of targeted cancer cell phagocytosis. Visiting. Bridging innate and adaptive anti-tumor immunity via therapeutic induction of targeted cancer cell phagocytosis. San Francisco, CA, US.
2018. Tumor immune-reprogramming with rationally-designed nanomedicines. Visiting. Tumor immune-reprogramming with rationally-designed nanomedicines. Gainesville, FL, US.
2018. Cancer Therapy without Targeting Cancer Cells. Visiting. Cancer Therapy without Targeting Cancer Cells. Dallas, TX, US.
2018. 4-D Visualization of the Brain. Visiting. 4-D Visualization of the Brain. Durham, NC, US.
2018. Taming phagocytosis to enhance cancer immunotherapy. Visiting. Taming phagocytosis to enhance cancer immunotherapy. Durham, NC, US.
2018. Brain immune-microenvironment modulation for therapy. Visiting. Brain immune-microenvironment modulation for therapy. Indianapolis, IN, US.
2016. Vascular normalization for enhanced CNS drug delivery. Invited. Vascular normalization for enhanced CNS drug delivery. Rochester, MN, US.
2015. Reaching your true potential: a hitchhiker's guide to brain surgery and beyond. Visiting. Reaching your true potential: a hitchhiker's guide to brain surgery and beyond. Orlando, FL, US.
2015. Engineering of the brain tumor microenvironment using nanoparticle design. Invited. Engineering of the brain tumor microenvironment using nanoparticle design. Chicago, IL, US.
2013. Nanotechnology for the neurosurgeon: The time is now. Visiting. Nanotechnology for the neurosurgeon: The time is now. Portland, OR, US.
2013. Nano neuro-oncology: There's plenty of room at the top too. Visiting. Nano neuro-oncology: There's plenty of room at the top too. Montreal, CA.
2013. Nanotechnology for brain tumors: The future is now. Visiting. Nanotechnology for brain tumors: The future is now. Jacksonville, FL, US.
2013. Neurosurgical nanotechnology: Targeting brain tumors and beyond National Institute of Neurological Disorders and Stroke (NINDS). Invited. Neurosurgical nanotechnology: Targeting brain tumors and beyond National Institute of Neurological Disorders and Stroke (NINDS). Bethesda, MD, US.
2012. Nanogeometry: Drug targeting and beyond. Visiting. Nanogeometry: Drug targeting and beyond. Houston, TX, US.

Less

Grant & Contract Support

Date:	2024 - 2029
Title:	Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1R01CA291876-01

Date:	2024 - 2027
Title:	In vivo chimeric antigen receptor macrophage (ChARMs) for cancer immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2023 - 2028
Title:	Friend to Foe: Activating innate functionality of glioma myeloid stroma to drive anti-tumor immunity
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2023 - 2027
Title:	Engineering in vivo chimeric antigen receptor macrophages (CARMs) using mRNA-exosomes for cancer immunotherapy
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1R01CA284108-01

Date:	2022 - 2024
Title:	Microbial mediated STING Activation for Glioblastoma Immunotherapy
Funding Source:	American Brain Tumor Association
Role:	Mentor

Date:	2022 - 2024
Title:	Reversing aging-associated resistance to cancer immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2022 - 2026
Title:	Glioblastoma immunotherapy with dual phagocytosis checkpoint blockade
Funding Source:	American Cancer Association-Research Scholar Grant
Role:	Co-I

Date:	2022 - 2024
Title:	Microbial-inspired STING Activation for Glioblastoma Immunotherapy
Funding Source:	Uncle Kory Foundation
Role:	PI

Date:	2022 - 2026
Title:	Break Through Cancer Glioblastoma Team
Funding Source:	Research Alliance between MIT, Dana Farber, MD Anderson, Memorial Sloan Kettering and Johns Hopkins University
Role:	Co-I

Date:	2021 - 2023
Title:	Aging, cancer and the fountain of immunological youth: The effect of aging on cancer immunotherapy
Funding Source:	Sabin Fellowship Award
Role:	PI

Date:	2021 - 2026
Title:	Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
Funding Source:	NIH/NINDS
Role:	Co-I
ID:	1R01NS117828-01A1

Date:	2021 - 2026
Title:	S100a4 Mediated Immune Suppression in GBM
Funding Source:	NIH/NINDS
Role:	Co-I
ID:	1R01NS121405-01

Date:	2020 - 2023
Title:	Clinical Development of CAR T Cell Therapy Targeting CD70 in Primary Glioblastoma
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	W81XWH-20-1-0726

Date:	2019 - 2024
Title:	SPORE in Brain Cancer – Animal Core
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	2 P50 CA127001-11A1

Date:	2019 - 2023
Title:	Microfluidics-array based sorting, isolation and RNA analysis of single extracellular vesicles
Funding Source:	NIH/NCATS
Role:	Co-PI
ID:	1UG3 TR002884 -02

Date:	2019 - 2021
Title:	Microfluidics-array based sorting, isolation and RNA analysis of single extracellular vesicles
Funding Source:	NIH/NCATS
Role:	PI
ID:	1UG3TR002884-01

Date:	2019 - 2022
Title:	A fusion protein bispecific phagocyte engager for targeted breast cancer immunotherapy
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	BC180673

Date:	2018 - 2021
Title:	Impact of ApoE2 on age-related conditions
Funding Source:	NIH/NIA
Role:	Co-I
ID:	R01AG57191

Date:	2018 - 2023
Title:	Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy
Funding Source:	NIH/NINDS
Role:	PI
ID:	1R01NS104315A

Date:	2018 - 2019
Title:	A Novel Bi-Specific Antibody for Glioblastoma Immunotherapy
Funding Source:	Merck-EMD Serono
Role:	PI
ID:	BU00154360

Date:	2018 - 2019
Title:	Enhancing Cancer Immunotherapy
Funding Source:	Mayo Clinic Department of Business Development
Role:	PI
ID:	BU91574017

Date:	2018 - 2019
Title:	Multivalent Biologics for Immune Detection of Cancer
Funding Source:	Zymeworks Inc
Role:	PI
ID:	BU00167857

Date:	2017 - 2019
Title:	Advanced Iimmune-Nano Imaging for Cancer Therapy
Funding Source:	Mayo Clinic Strawn Family Research Award
Role:	PI
ID:	91574002

Date:	2017 - 2019
Title:	GABA Reactivates Hepatocytes in Aged Liver
Funding Source:	NIH/NIA R21
Role:	Co-I
ID:	1R21AG052822

Date:	2017 - 2019
Title:	Engineering a Bi-Specific Nano-Engager for Targeted Glioblastoma Immunotherapy
Funding Source:	Florida Center for Brain Tumor Research
Role:	PI
ID:	UFDSP00011933

Date:	2017 - 2021
Title:	Pathogenic effects of plasma ApoE on CNS function and Alzheimer's Disease
Funding Source:	NIH/NIA R21
Role:	Co-I
ID:	1R21AG057981

Date:	2016 - 2019
Title:	High Throughput Multiplexed Immunological Profiling of Glioblastoma using Nano-Bioconjugates
Funding Source:	Mayo Clinic Helene Houle Award for Neurologic Surgery
Role:	PI
ID:	91574009

Date:	2016 - 2019
Title:	Nanomedicines for Cancer Theranostics
Funding Source:	Mayo Clinic DeMars Award for Nanomedicine
Role:	PI
ID:	91574002

CV information above last modified March 28, 2025

Betty Kim, MD, PhD, FRCSC, FAANS

In the News

Study opens new avenue for immunotherapy drug development

Scientists develop novel mRNA delivery method using extracellular vesicles

Physician-scientist: I found my sense of belonging at MD Anderson

MD Anderson announces 2021 class of Andrew Sabin Family Fellows

Nanomedicine: Small particles with huge possibilities for cancer care

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Kim Laboratory

Neurosurgery Department

Surgery Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer